Clinical trial NCT03350529 - References

Benign Prostatic Hyperplasia — MRI Guided Transurethral HIFU for Various Prostate Diseases

Citation(s)

•   1
  www.cancerregistry.fi
•   4
  McDougal WS, Wein AJ, Kavoussi LR, et al: Campbell-Walsh Urology 10th Edition Review E-Book. A Saunders Title; 2011. p. 704
•   Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L
  Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer. 2004 Jun 1;100(11):2362-6. doi: 10.1002/cncr.20243.
•   Bechis SK, Carroll PR, Cooperberg MR
  Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011 Jan 10;29(2):235-41. doi: 10.1200/JCO.2010.30.2075. Epub 2010 Dec 6.
•   Boyes A, Tang K, Yaffe M, Sugar L, Chopra R, Bronskill M
  Prostate tissue analysis immediately following magnetic resonance imaging guided transurethral ultrasound thermal therapy. J Urol. 2007 Sep;178(3 Pt 1):1080-5. doi: 10.1016/j.juro.2007.05.011. Epub 2007 Jul 20.
•   Brierly RD, Mostafid AH, Kontothanassis D, Thomas PJ, Fletcher MS, Harrison NW
  Is transurethral resection of the prostate safe and effective in the over 80-year-old? Ann R Coll Surg Engl. 2001 Jan;83(1):50-3.
•   Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boeve ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strolin P, van Muilekom E, Schroder FH, Bangma CH, Roobol MJ
  Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 2013 Apr;63(4):597-603. doi: 10.1016/j.eururo.2012.11.005. Epub 2012 Nov 12.
•   Burtnyk M, Chopra R, Bronskill MJ
  Quantitative analysis of 3-D conformal MRI-guided transurethral ultrasound therapy of the prostate: theoretical simulations. Int J Hyperthermia. 2009 Mar;25(2):116-31. doi: 10.1080/02656730802578802.
•   Burtnyk M, Hill T, Cadieux-Pitre H, Welch I
  Magnetic resonance image guided transurethral ultrasound prostate ablation: a preclinical safety and feasibility study with 28-day followup. J Urol. 2015 May;193(5):1669-75. doi: 10.1016/j.juro.2014.11.089. Epub 2014 Nov 22.
•   Chin JL, Billia M, Relle J, Roethke MC, Popeneciu IV, Kuru TH, Hatiboglu G, Mueller-Wolf MB, Motsch J, Romagnoli C, Kassam Z, Harle CC, Hafron J, Nandalur KR, Chronik BA, Burtnyk M, Schlemmer HP, Pahernik S
  Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial. Eur Urol. 2016 Sep;70(3):447-55. doi: 10.1016/j.eururo.2015.12.029. Epub 2016 Jan 6.
•   Chopra R, Baker N, Choy V, Boyes A, Tang K, Bradwell D, Bronskill MJ
  MRI-compatible transurethral ultrasound system for the treatment of localized prostate cancer using rotational control. Med Phys. 2008 Apr;35(4):1346-57. doi: 10.1118/1.2841937.
•   Chopra R, Colquhoun A, Burtnyk M, N'djin WA, Kobelevskiy I, Boyes A, Siddiqui K, Foster H, Sugar L, Haider MA, Bronskill M, Klotz L
  MR imaging-controlled transurethral ultrasound therapy for conformal treatment of prostate tissue: initial feasibility in humans. Radiology. 2012 Oct;265(1):303-13. doi: 10.1148/radiol.12112263. Epub 2012 Aug 28.
•   Chopra R, Tang K, Burtnyk M, Boyes A, Sugar L, Appu S, Klotz L, Bronskill M
  Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedback. Phys Med Biol. 2009 May 7;54(9):2615-33. doi: 10.1088/0031-9155/54/9/002. Epub 2009 Apr 8.
•   Cooperberg MR, Moul JW, Carroll PR
  The changing face of prostate cancer. J Clin Oncol. 2005 Nov 10;23(32):8146-51. doi: 10.1200/JCO.2005.02.9751.
•   Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F
  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
•   Haider MA, van der Kwast TH, Tanguay J, Evans AJ, Hashmi AT, Lockwood G, Trachtenberg J
  Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol. 2007 Aug;189(2):323-8. doi: 10.2214/AJR.07.2211.
•   Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology
  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014 Jan;65(1):124-37. doi: 10.1016/j.eururo.2013.09.046. Epub 2013 Oct 6.
•   Heidenreich A, Porres D, Pfister D
  The Role of Palliative Surgery in Castration-Resistant Prostate Cancer. Oncol Res Treat. 2015;38(12):670-7. doi: 10.1159/000442268. Epub 2015 Nov 23.
•   Heidenreich A, Richter S, Thuer D, Pfister D
  Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol. 2010 Mar;57(3):437-43. doi: 10.1016/j.eururo.2009.02.041. Epub 2009 Mar 13.
•   Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU
  Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis. 2011 Mar;14(1):46-52. doi: 10.1038/pcan.2010.16. Epub 2010 May 25.
•   Klotz L
  Expectant management with selective delayed intervention for favorable risk prostate cancer. Urol Oncol. 2002 Sep-Oct;7(5):175-9. doi: 10.1016/s1078-1439(02)00183-7.
•   Krupski TL, Stukenborg GJ, Moon K, Theodorescu D
  The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer. BJU Int. 2010 Nov;106(10):1477-83. doi: 10.1111/j.1464-410X.2010.09356.x.
•   Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL
  Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):915-28. doi: 10.1016/s0360-3016(03)00632-1.
•   Lafon C, Koszek L, Chesnais S, Theillere Y, Cathignol D
  Feasibility of a transurethral ultrasound applicator for coagulation in prostate. Ultrasound Med Biol. 2004 Jan;30(1):113-22. doi: 10.1016/j.ultrasmedbio.2003.10.009.
•   Marszalek M, Ponholzer A, Rauchenwald M, Madersbacher S
  Palliative transurethral resection of the prostate: functional outcome and impact on survival. BJU Int. 2007 Jan;99(1):56-9. doi: 10.1111/j.1464-410X.2006.06529.x. Epub 2006 Oct 11.
•   McNeal JE
  Anatomy of the prostate and morphogenesis of BPH. Prog Clin Biol Res. 1984;145:27-53. No abstract available.
•   Mearini L, Porena M
  Transrectal high-intensity focused ultrasound for the treatment of prostate cancer: past, present, and future. Indian J Urol. 2010 Jan-Mar;26(1):4-11. doi: 10.4103/0970-1591.60436.
•   Michielsen DP, Coomans D, Engels B, Braeckman JG
  Bipolar versus monopolar technique for palliative transurethral prostate resection. Arch Med Sci. 2010 Oct;6(5):780-6. doi: 10.5114/aoms.2010.17095. Epub 2010 Oct 26.
•   Nguyen PL, D'Amico AV, Lee AK, Suh WW
  Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007 Oct 1;110(7):1417-28. doi: 10.1002/cncr.22941.
•   Partanen A, Yerram NK, Trivedi H, Dreher MR, Oila J, Hoang AN, Volkin D, Nix J, Turkbey B, Bernardo M, Haines DC, Benjamin CJ, Linehan WM, Choyke P, Wood BJ, Ehnholm GJ, Venkatesan AM, Pinto PA
  Magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy of the prostate: a preclinical study with radiological and pathological correlation using customised MRI-based moulds. BJU Int. 2013 Aug;112(4):508-16. doi: 10.1111/bju.12126. Epub 2013 Jun 7.
•   Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC
  Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004 Sep 15;96(18):1358-67. doi: 10.1093/jnci/djh259.
•   Ramsay E, Mougenot C, Kohler M, Bronskill M, Klotz L, Haider MA, Chopra R
  MR thermometry in the human prostate gland at 3.0T for transurethral ultrasound therapy. J Magn Reson Imaging. 2013 Dec;38(6):1564-71. doi: 10.1002/jmri.24063. Epub 2013 Feb 25.
•   Ramsay E, Mougenot C, Staruch R, Boyes A, Kazem M, Bronskill M, Foster H, Sugar L, Haider M, Klotz L, Chopra R
  Evaluation of Focal Ablation of Magnetic Resonance Imaging Defined Prostate Cancer Using Magnetic Resonance Imaging Controlled Transurethral Ultrasound Therapy with Prostatectomy as the Reference Standard. J Urol. 2017 Jan;197(1):255-261. doi: 10.1016/j.juro.2016.06.100. Epub 2016 Aug 18.
•   Reeve BB, Stover AM, Jensen RE, Chen RC, Taylor KL, Clauser SB, Collins SP, Potosky AL
  Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans: a population-based study. Cancer. 2012 Nov 15;118(22):5679-87. doi: 10.1002/cncr.27578. Epub 2012 Apr 27.
•   Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H
  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74. doi: 10.1016/j.ijrobp.2006.04.029.
•   Ross AB, Diederich CJ, Nau WH, Gill H, Bouley DM, Daniel B, Rieke V, Butts RK, Sommer G
  Highly directional transurethral ultrasound applicators with rotational control for MRI-guided prostatic thermal therapy. Phys Med Biol. 2004 Jan 21;49(2):189-204. doi: 10.1088/0031-9155/49/2/002.
•   Sammet S, Partanen A, Yousuf A, Sammet CL, Ward EV, Wardrip C, Niekrasz M, Antic T, Razmaria A, Farahani K, Sokka S, Karczmar G, Oto A
  Cavernosal nerve functionality evaluation after magnetic resonance imaging-guided transurethral ultrasound treatment of the prostate. World J Radiol. 2015 Dec 28;7(12):521-30. doi: 10.4329/wjr.v7.i12.521.
•   Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, Witjes JA
  Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol. 2011 Jun;59(6):962-77. doi: 10.1016/j.eururo.2011.02.034. Epub 2011 Feb 23.
•   Siddiqui K, Chopra R, Vedula S, Sugar L, Haider M, Boyes A, Musquera M, Bronskill M, Klotz L
  MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies. Urology. 2010 Dec;76(6):1506-11. doi: 10.1016/j.urology.2010.04.046. Epub 2010 Aug 14.
•   Sommer G, Pauly KB, Holbrook A, Plata J, Daniel B, Bouley D, Gill H, Prakash P, Salgaonkar V, Jones P, Diederich C
  Applicators for magnetic resonance-guided ultrasonic ablation of benign prostatic hyperplasia. Invest Radiol. 2013 Jun;48(6):387-94. doi: 10.1097/RLI.0b013e31827fe91e.
•   Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC
  Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011 Jun 20;29(18):2574-81. doi: 10.1200/JCO.2010.33.2999. Epub 2011 May 23.
•   Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, Emberton M
  New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol. 2017 Jan;71(1):17-34. doi: 10.1016/j.eururo.2016.08.044. Epub 2016 Aug 29.
•   van Tol-Geerdink JJ, Leer JW, van Oort IM, van Lin EJ, Weijerman PC, Vergunst H, Witjes JA, Stalmeier PF
  Quality of life after prostate cancer treatments in patients comparable at baseline. Br J Cancer. 2013 May 14;108(9):1784-9. doi: 10.1038/bjc.2013.181. Epub 2013 Apr 23.
•   Wasserman NF
  Benign prostatic hyperplasia: a review and ultrasound classification. Radiol Clin North Am. 2006 Sep;44(5):689-710, viii. doi: 10.1016/j.rcl.2006.07.005.
•   Won AC, Gurney H, Marx G, De Souza P, Patel MI
  Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int. 2013 Aug;112(4):E250-5. doi: 10.1111/bju.12169.

Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer

Details for clinical trial NCT03350529